News
Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases. Promising results, but Phase ...
Market Trends, Business Strategies, Competitive Intelligence, Clinical Trials, and Patent Trends Driving Growth from 2024 to 2029"Boston, July 10, 2025 (GLOBE NEWSWIRE) -- According to the latest ...
In recent years, the FDA has approved three complement inhibitors for gMG -- eculizumab (Soliris), ravulizumab (Ultomiris), ...
FDA designates MB-101 CAR T-cell therapy for glioblastoma, highlighting its potential in treating aggressive brain tumors ...
I’ve endured numerous rounds of radiation and taken thousands of pills—but CAR-T is the most effective therapy I’ve completed yet.
Several ASX-listed biotechs are advancing cell therapies to capture a share of a global market projected to reach US$48 ...
Despite promising science, Precigen has long-faced severe financial challenges and a very short cash runway into 2026. Click ...
Previously, due to the risk of cytokine release syndrome and neurological toxicities, many CAR T-cell therapies included a REMS requirement.
Experimental treatment could offer a safer, cheaper alternative to CAR-T-cell therapies for disorders such as lupus.
Legend Biotech Corp. ADR advanced stock charts by Barron's. View LEGN historical stock data and compare to other stocks, and exchanges.
A team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and ...
While data is promising, many questions remain about topics such as timing and doses in the treatment of hematologic malignancies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results